论文部分内容阅读
目的观察非布司他对高尿酸血症患者炎性因子的影响及疗效。方法选取医院收治的高尿酸血症患者120例为研究对象,随机分为对照组和观察组,每组60例。2组患者均给予常规治疗,对照组给予苯溴马隆片治疗,观察组给予非布司他治疗,观察2组治疗后炎性因子的变化及临床疗效。结果观察组治疗总有效率为95.0%,高于对照组的80.0%(P<0.05)。治疗后,2组炎性因子水平较治疗前均降低,且观察组炎性因子水平低于对照组(P<0.05)。2组患者在治疗过程中均未出现严重不良反应。结论非布司他定治疗高尿酸血症对患者的炎性因子具有显著性影响,可有效改善临床疗效,值得推广应用。
Objective To observe the effect of febuxostat on inflammatory cytokines in patients with hyperuricemia and its curative effect. Methods A total of 120 patients with hyperuricemia admitted to hospital were selected as study subjects and randomly divided into control group and observation group, with 60 cases in each group. The patients in both groups were given routine treatment. The control group was treated with benzbromarone tablets. The observation group was treated with febuxostat. The changes of inflammatory factors and the clinical effects were observed in the two groups. Results The total effective rate of observation group was 95.0%, higher than 80.0% of control group (P <0.05). After treatment, the levels of inflammatory cytokines in both groups were lower than those before treatment, and the levels of inflammatory cytokines in the observation group were lower than those in the control group (P <0.05). Two groups of patients in the course of treatment did not appear serious adverse reactions. Conclusion Non-brevisostat treatment of hyperuricemia has significant effect on inflammatory factors in patients, which can effectively improve the clinical efficacy and is worth popularizing and applying.